Patients

PharmaEssentia's novel pegylation technology platform has yielded our lead product, Ropeginterferon alfa-2b, which is currently being explored in several indications. Ropeginterferon alfa-2b is a novel engineered interferon alpha 2b, designed to be the most purer interferon alpha designed. In the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biological activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. Our pegylation technology platform is designed to increase the protein drug's efficacy by prolonging its circulation in the bloodstream. Utilizing its innovative 40K PEG and its novel pegylation technology platform by combining protein engineering and PEG-related chemistry, we creates novel products for better disease treatment. Compared with the similar drugs on the market, including PEG-Intron (Merck) and Pegasys (Roche), Ropeginterferon alfa-2b shows not only the most effective PK/PD data but also reduces severe side effects.

Our Ropeginterferon alfa-2b offers the following advantages:

• The predominantly single-site-specific conjugation pegylation, resulting in a >90% single isomer composition, it leads to a superior PK and safety to other Interferons and hydroxyurea (HU).
• Much higher MTD than Pegasys and PEG-Intron, resulting in a dosing of one injection every 2 weeks (potentially every 4 weeks) vs. Pegasys and PEG-Introns' once weekly injections.
• Ropeginterferon alfa-2b is potentially offers disease modification and prevention of progression (SMF, other malignancies) and JAK2 burden reduction.

When it comes to cancer, no one should fight alone. That's why PharmaEssentia is collaborating with the myeloproliferative neoplasms (MPN) community to advocate for new options and improved quality of life for patients living with MPNs and rare blood cancers like polycythemia vera (PV).

Our strong partnerships with advocacy groups, patients and care partners drives our commitment to their fight. We are allies in their efforts to raise awareness of the burden of rare blood cancers, and share their goal of improving quality of life for those impacted by them through education and helping patients to find optimal care. These organizations are resources for patients and their families to find information and make connections to support them in their disease journeys.